Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance
Ming‐Tain Lai, Meizhen Feng, Min Xu, Winnie Ngo, Tracy L. Diamond, Carey Hwang, Jay A. Grobler, Daria J. Hazuda, Ernest Asante‐Appiah
Abstract
). DOR/ISL exhibited a higher barrier to resistance than DOR/3TC and dolutegravir (DTG)/3TC. Resistance analysis showed no emergence of substitutions at F227, an observation consistent with its ability to confer hypersusceptibility to ISL. Overall, the data demonstrate that DOR/ISL creates a 2-drug combination with a higher barrier to resistance, consistent with the reported clinical activity.
Topics & Concepts
DolutegravirLamivudineNucleoside Reverse Transcriptase InhibitorEmtricitabineResistance mutationReverse-transcriptase inhibitorReverse transcriptaseVirologyZidovudineDrug resistanceBiologyNucleosideStavudinePharmacologyHuman immunodeficiency virus (HIV)VirusViral loadMicrobiologyGeneticsAntiretroviral therapyHepatitis B virusRNAViral diseaseGeneHIV/AIDS drug development and treatmentHIV Research and TreatmentBiochemical and Molecular Research